- Home
- NTRB vs ANVS Comparison
NTRB vs ANVS Comparison
Compare NTRB & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | ANVS |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 76.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NTRB | ANVS |
|---|---|---|
| Price | $5.66 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 42.9K | ★ 928.3K |
| Earning Date | 05-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,036,651.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $1.30 |
| 52 Week High | $8.63 | $5.50 |
Technical Indicators
Market Signals| Indicator | NTRB | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 79.17 | 25.47 |
| Support Level | $4.23 | N/A |
| Resistance Level | $6.41 | $2.02 |
| Average True Range (ATR) | 0.58 | 0.10 |
| MACD | 0.17 | -0.06 |
| Stochastic Oscillator | 86.68 | 1.86 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.